Belgium has strong biobanks, but many still experience the system as fragmented and hard to navigate when conducting biomedical research. Experts in Belgium are arguing that we need to treat biobanks as shared infrastructure — data-rich platforms with predictable access, sustainable funding, and governance built around patient trust.
Big pharma may be powerful, profitable, and global, but it cannot rely on scale alone to secure the future of medicine. As patents expire and blockbuster revenues decline, pharmaceutical companies increasingly depend on biotech startups to generate new ideas, products, and platforms. Yet many early-stage biotechs are struggling to raise the capital they need to survive. If that trend persists, the consequences will reach far beyond startups — weakening pharma pipelines and delaying future health solutions for patients.
Cooling is often treated as a stable constant in pharmaceutical processes — until its fails. Deviations rarely happen unexpectedly; they develop gradually and often go unnoticed for too long. By the time they are detected, product quality may already be compromised. So how can companies ensure that their cooling systems remain stable in real-world conditions?
Antwerp researcher Rosa Rademakers has won the Breakthrough Prize in the US — one of the world’s most prestigious science awards. Rademakers received the prize and more than 2.5 million euros for her groundbreaking discovery that a rare genetic mutation plays a key role in both frontotemporal dementia and ALS.
Belgium has strong biobanks, but many still experience the system as fragmented and hard to navigate when conducting biomedical research. Experts in Belgium are arguing that we need to treat biobanks as shared infrastructure — data-rich platforms with predictable access, sustainable funding, and governance built around patient trust.
Big pharma may be powerful, profitable, and global, but it cannot rely on scale alone to secure the future of medicine. As patents expire and blockbuster revenues decline, pharmaceutical companies increasingly depend on biotech startups to generate new ideas, products, and platforms. Yet many early-stage biotechs are struggling to raise the capital they need to survive. If that trend persists, the consequences will reach far beyond startups — weakening pharma pipelines and delaying future health solutions for patients.
Cooling is often treated as a stable constant in pharmaceutical processes — until its fails. Deviations rarely happen unexpectedly; they develop gradually and often go unnoticed for too long. By the time they are detected, product quality may already be compromised. So how can companies ensure that their cooling systems remain stable in real-world conditions?
Antwerp researcher Rosa Rademakers has won the Breakthrough Prize in the US — one of the world’s most prestigious science awards. Rademakers received the prize and more than 2.5 million euros for her groundbreaking discovery that a rare genetic mutation plays a key role in both frontotemporal dementia and ALS.
Europe has long positioned itself as a global leader in life sciences. With world-class research institutions and a steady pipeline of scientific breakthroughs, that claim is well founded. But at the heart of the ecosystem, there is a growing disconnect. Is Europe equipped to build and retain globally competitive companies, or is it just a generator of innovation for others to scale?
Belgium has strong biobanks, but many still experience the system as fragmented and hard to navigate when conducting biomedical research. Experts in Belgium are arguing that we need to treat biobanks as shared infrastructure — data-rich platforms with predictable access, sustainable funding, and governance built around patient trust.
Big pharma may be powerful, profitable, and global, but it cannot rely on scale alone to secure the future of medicine. As patents expire and blockbuster revenues decline, pharmaceutical companies increasingly depend on biotech startups to generate new ideas, products, and platforms. Yet many early-stage biotechs are struggling to raise the capital they need to survive. If that trend persists, the consequences will reach far beyond startups — weakening pharma pipelines and delaying future health solutions for patients.
Cooling is often treated as a stable constant in pharmaceutical processes — until its fails. Deviations rarely happen unexpectedly; they develop gradually and often go unnoticed for too long. By the time they are detected, product quality may already be compromised. So how can companies ensure that their cooling systems remain stable in real-world conditions?
Antwerp researcher Rosa Rademakers has won the Breakthrough Prize in the US — one of the world’s most prestigious science awards. Rademakers received the prize and more than 2.5 million euros for her groundbreaking discovery that a rare genetic mutation plays a key role in both frontotemporal dementia and ALS.
Europe has long positioned itself as a global leader in life sciences. With world-class research institutions and a steady pipeline of scientific breakthroughs, that claim is well founded. But at the heart of the ecosystem, there is a growing disconnect. Is Europe equipped to build and retain globally competitive companies, or is it just a generator of innovation for others to scale?